WHOOP has never had a screen. No step counter glowing on your wrist, no notification buzzing mid-run, no social features designed to keep you scrolling instead of sleeping. The device tracks three things strain, recovery, and sleep with continuous, clinical precision, and delivers the data through a subscription service that turns the numbers into actionable guidance.

That philosophy, uncompromised for fourteen years, has now attracted $575 million in a Series G round that values the Boston-based company at $10.1 billion. The raise is nearly three times WHOOP's $3.6 billion valuation from 2021, and it comes as the company disclosed that it ended 2025 with a $1.1 billion annual bookings run rate, 103% year-on-year bookings growth, and a cash-flow positive business serving 2.5 million members worldwide.

The round was led by Collaborative Fund and drew an unusually broad set of institutional and strategic investors. The Qatar Investment Authority and Mubadala Investment Company two of the world's most significant sovereign wealth funds participated alongside Abbott, the global medical device and diagnostics company, and Mayo Clinic, one of the most respected healthcare institutions in the world. The involvement of Abbott and Mayo Clinic is not incidental. WHOOP has been publicly positioning itself as a play on the longevity and preventive health movements the argument that continuous biometric monitoring, not reactive clinical care, is where the future of health management lies. Having two healthcare giants as investors backstops that narrative with institutional credibility.

The athlete-investor roster includes Cristiano Ronaldo, LeBron James, Rory McIlroy, Reggie Miller, Niall Horan, Virgil van Dijk, Mathieu van der Poel, and Shane Lowry. Ronaldo, named a global ambassador, stated that WHOOP had become one of the most important tools in his health management. These are not celebrity endorsement deals dressed up as investments. At the level these athletes operate, recovery data is competitive infrastructure and the fact that the people who train hardest in the world choose to invest in the tool they rely on most is a more credible testimonial than any advertising campaign.

Founded in 2012 by Will Ahmed, who came up with the concept while a student at Harvard, WHOOP has grown by staying stubbornly narrow. It has never tried to be a smartwatch. It has never tried to compete with the Apple Watch on features. The subscription model unusual for consumer hardware when WHOOP launched it has been vindicated by the recurring revenue it generates and the engagement depth it implies: people who pay monthly to access their own biometric data are deeply committed users.

The $10.1 billion valuation is not just a number. It is a verdict on the category WHOOP has been building toward since 2012: that serious health tracking, untethered from the distraction layer of a smartphone-on-your-wrist, is a large and defensible market. CEO Will Ahmed has indicated the next step is an IPO. The plan to hire up to 600 new roles a 75% increase in headcount signals a company moving from proving the model to scaling it.